Is meropenem effective for treating infections caused by Alcaligenes species?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Meropenem Coverage of Alcaligenes

Meropenem demonstrates good in vitro activity against Alcaligenes species and should be considered a reasonable treatment option, though susceptibility testing is essential given emerging resistance patterns.

Evidence-Based Assessment

FDA-Approved Spectrum

The FDA label for meropenem does not explicitly list Alcaligenes species among its approved indications 1. The labeled organisms are limited to specific pathogens in complicated skin/soft tissue infections, intra-abdominal infections, and meningitis.

In Vitro Activity Data

Historical susceptibility (1991): Early comparative studies demonstrated that meropenem was more active than imipenem against Alcaligenes isolates, showing superior in vitro potency 2.

Contemporary resistance patterns (2020): More recent clinical data reveals concerning trends:

  • In a 61-patient case series of Alcaligenes faecalis infections, meropenem maintained a 66.7% susceptibility rate in 2019 3
  • This represents declining susceptibility compared to historical data
  • Extensively drug-resistant (XDR) Alcaligenes infections have emerged since 2018 3
  • 60.7% of infected patients had received intravenous antibiotics within 3 months prior, suggesting selection pressure 3

Clinical Context

Key considerations:

  • Alcaligenes infections are typically opportunistic, occurring in patients with prior antibiotic exposure 3
  • 83.6% of cases involve polymicrobial infections 3
  • Most common infection sites: urinary tract (cystitis, pyelonephritis), diabetic foot, pneumonia, and bacteremia 3

Treatment Recommendations

When to Use Meropenem

  • Susceptibility testing is mandatory - do not use empirically without culture data
  • Consider meropenem when susceptibility is confirmed (MIC ≤2 mg/L for most gram-negatives)
  • Particularly appropriate for severe infections (bacteremia, pneumonia, complicated urinary tract infections)

Dosing Strategy

For confirmed susceptible Alcaligenes infections:

  • Standard dosing: 1 gram IV every 8 hours for adults
  • Severe infections or higher MICs: Consider extended infusion (3-hour infusion) to optimize time above MIC 4, 5
  • Therapeutic drug monitoring should be considered in critically ill patients 5

Critical Pitfalls

⚠️ Do not assume susceptibility - the 66.7% susceptibility rate means one-third of isolates are resistant 3

⚠️ Alternative agents may be needed - if meropenem MIC is elevated or resistance is documented, consider:

  • Ceftazidime (also showed 66.7% susceptibility) 3
  • Avoid ciprofloxacin and piperacillin-tazobactam (both <50% susceptibility) 3

⚠️ XDR isolates are emerging - have infectious disease consultation for extensively drug-resistant cases 3

Monitoring

  • Obtain susceptibility testing before initiating therapy
  • Monitor clinical response within 48-72 hours
  • Consider repeat cultures if clinical improvement is inadequate
  • Renal function monitoring is essential given meropenem's renal elimination 1

References

Related Questions

If a patient on meropenem (dat 8 regimen) was planned for a 14‑day course but was accidentally discontinued, should the day before discontinuation count toward the total treatment duration when the therapy is restarted?
What antibiotic regimen should be used for a patient with peritonitis who has received meropenem for five days without clinical improvement?
In a patient with a severe infection whose isolate is susceptible to meropenem and imipenem, should ertapenem still be used?
Can meropenem be administered to a 13-year-old girl with severe community-acquired pneumonia and pleural effusion?
How should amikacin (amikacin) and meropenem (meropenem) be dosed, adjusted for renal function, monitored, and for how long used in serious multidrug‑resistant gram‑negative infections?
How should I apply a topical corticosteroid cream to treat vasculitis of the legs?
What is the appropriate initial acute treatment for a 29-year-old patient with schizophrenia presenting with an acute psychotic episode, who previously responded well to clozapine or lurasidone (Lurasidone) but has been medication-free for six months, with normal vital signs and laboratory results?
What is the recommended treatment for an immunocompetent adult with herpes simplex virus–positive lesions at the top of the gluteal crease?
Which angiotensin-converting enzyme (ACE) inhibitor should be initiated for a patient with hypertension, including recommended starting dose, titration schedule, and monitoring parameters?
Does this 73-year-old woman with coronary artery disease, hypertension, dyslipidemia, diabetes, single left kidney, atrial fibrillation on rivaroxaban, presenting with 5–6 hours of oppressive precordial chest pain, dyspnea on minimal effort, orthopnea requiring two pillows, lower‑extremity edema, and an electrocardiogram showing atrial fibrillation with high‑grade atrioventricular block, complete right bundle branch block, and right‑axis deviation need to be referred to the emergency department?
What are the advantages of progesterone-only therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.